2024 年度涉及财务公司关联交易的 存款、贷款等金融业务的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 2024 年度涉及财务公司关联交易的存款、贷款等金融 | 3-3 | | 业务汇总表 | | 关于中粮生物科技股份股份有限公司 2024 年度涉及财务公司关联交易的存款、贷款等金融业务的 专项说明 XYZH/2025BJAA11B0121 关于中粮生物科技股份有限公司 专项说明（续） XYZH/2025BJAA11B0121 中粮生物科技股份有限公司 中粮生物科技股份有限公司 中粮生物科技股份有限公司全体股东： 我们按照中国注册会计师审计准则审计了中粮生物科技股份有限公司(以下简称中 粮科技公司) 2024年度财务报表，包括2024年12月31日的合并及母公司资产负债表、 2024年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变 动表，以及相关财务报表附注，并于2024年4月24日出具了XYZH/2025BJAA11B0117号无 保留意见的审计报告。 根据深圳证券交易所相关规定，中粮科技公司编制了本专项说明所附的《中粮生物 科技 ...

前十大流通股东累计持有： 109106.65万股，累计占流通股比： 58.77%，较上期变化： -426.56 万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0135 | -0.3267 | 104.13 | 0.5700 | | 每股净资产（元） | 5.66 | 5.6 | 1.07 | 6.49 | | 每股公积金(元) | 3.28 | 3.29 | -0.3 | 3.29 | | 每股未分配利润(元) | 0.77 | 0.76 | 1.32 | 1.69 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 200.53 | 203.79 | -1.6 | 199.18 | | 净利润(亿元) | 0.25 | -6.02 | 104.15 | 10.59 | | 净资产收益率(%) | 0.24 | -5.34 | 104.49 | 9.02 | 数据四舍五入，查看更多 ...

| 应出席 | 现场出席 | 以通讯方式参 | 委托出席 | 缺席 | 是否连续两次未 | | --- | --- | --- | --- | --- | --- | | 次数 | （次） | 加会议次数 | 次数 | 次数 | 亲自出席会议 | | 12 | 1 | 11 | 0 | 0 | 否 | 中粮生物科技股份有限公司 2024年度独立董事述职报告 2024 年，本人任职中粮生物科技股份有限公司（以下简称公司）第八届、 第九届董事会独立董事。本人严格按照《公司法》《关于在上市公司建立独立董 事的指导意见》、《关于加强社会公众股股东权益保护的若干规定》《公司章程》 以及公司董事会专业委员会工作规程等相关法律法规的规定和要求，保持独立董 事应有的独立性，勤勉尽责，促进公司的规范运作，为公司经营管理建言献策， 独立公正地行使独立董事的职权，维护了全体股东尤其是中小股东的合法权益。 现将 2024 年度履职情况报告如下： 一、出席会议情况 2024年度出席董事会会议情况具体如下： 三、2024 年，本人没有对公司董事会议案和非董事会议案的其他事项提出 异议；没有提议召开董事会、临时股东大会；没有提议解聘会计师 ...

根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》及《公 司章程》等有关规定，中粮生物科技股份有限公司（以下简称公司）独立董事于 2025 年 4 月 24 日召开第九届董事会 2025 年第 1 次独立董事专门会议，会议应 参加表决董事 3 人，实际参加表决的董事共 3 人，参加表决的董事有：陈国强先 生、张念春先生、汪平先生，独立董事就以下议题开专门会议，审查意见如下： 一、 关于公司 2025 年度日常关联交易预计事项的审核意见 公司 2025 年度日常关联交易预计事项，符合公司利益和股东利益最大化原 则，公司与关联企业之间的业务往来按一般市场经营规则进行，与其他业务往来 企业同等对待。公司与关联企业之间不可避免的关联交易，遵照公平、公正的市 场原则，交易价格将按照市场规律，以市场同类交易标的的价格为依据。交货、 付款均按相关合同条款执行。公司与关联方交易价格依据市场公允价格确定，符 合公司生产经营和持续发展的需要，不存在损害公司和全体股东利益的行为。日 常关联交易的实施不会对公司独立性产生不利影响，公司不会因此类交易对关联 方产生依赖或被其控制。 作为公司独立董事，我们同意将该议案提交公司 ...

根据《上市公司独立董事管理办法》、《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 等要求，中粮生物科技股份有限公司（以下简称公司）董事会，就公司在任独立 董事陈国强先生、张念春先生、汪平先生 2024 年度保持独立性情况进行评估并 出具如下专项意见： 经核查公司独立董事的任职经历以及签署的相关自查文件，上述人员未在公 司担任除独立董事以外的任何职务，与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司 独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》中对独立董事独立性的相关要求。 中粮生物科技股份有限公司董事会 中粮生物科技股份有限公司 关于独立董事 2024 年度保持独立性情况的专项意见 董 事 会 2025 年 4 月 24 日 ...

中粮生物科技股份有限公司 2024 年，本人对公司有关事项发表独立意见，具体如下： 1.2024 年 4 月 23 日，对关于公司 2023 年度内部控制评价报告、关于公司 2024 年度日常关联交易事项、关于公司 2024-2025 年度向中粮财务有限责任公 司申请 41 亿元综合授信、关于公司限制性股票激励计划第三个解锁期解锁条件 未成就暨回购注 销部分限制性股票事项、关于对外担保情况及与关联方资金往 来情况专项说明等事项发表了独立意见。 2.2024 年 9 月 2 日，对关于提名公司第九届董事会非独立董事候选人、关 于提名公司第九届董事会独立董事候选人、关于聘请审计机构等事项发表了独立 意见。 3.2024 年 9 月 29 日，对关于聘任公司总经理、关于聘任公司高级管理人员 2024年度独立董事述职报告 2024 年，本人任职中粮生物科技股份有限公司（以下简称公司）第八届、 第九届董事会独立董事。本人严格按照《公司法》《关于在上市公司建立独立董 事的指导意见》、《关于加强社会公众股股东权益保护的若干规定》《公司章程》 以及公司董事会专业委员会工作规程等相关法律法规的规定和要求，保持独立董 事应有的独 ...

2024 年，本人任职中粮生物科技股份有限公司（以下简称公司）第九届董 事会独立董事。本人严格按照《公司法》《关于在上市公司建立独立董事的指导 意见》、《关于加强社会公众股股东权益保护的若干规定》《公司章程》以及公司 董事会专业委员会工作规程等相关法律法规的规定和要求，保持独立董事应有的 独立性，勤勉尽责，促进公司的规范运作，为公司经营管理建言献策，独立公正 地行使独立董事的职权，维护了全体股东尤其是中小股东的合法权益。现将 2024 年度履职情况报告如下： 中粮生物科技股份有限公司 2024年度独立董事述职报告 一、出席会议情况 2024年度出席董事会会议情况具体如下： | 应出席 | 现场出席 | 以通讯方式参 | 委托出席 | 缺席 | 是否连续两次未 | | --- | --- | --- | --- | --- | --- | | 次数 | （次） | 加会议次数 | 次数 | 次数 | 亲自出席会议 | | 5 | 0 | 5 | 0 | 0 | 否 | 2024年本人任职期间，公司共召开9次董事会，本人均参加会议审议会议的 各项议案，对有关议案进行表决，并对有关事项发表独立意见。本人注重运用自 ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥20.05 billion, a decrease of 1.60% compared to ¥20.38 billion in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥25.13 million, a significant increase of 104.18% from a loss of ¥601.63 million in 2023[20]. - The net cash flow from operating activities for 2024 was ¥155.81 million, down 92.04% from ¥1.96 billion in 2023[20]. - The total assets at the end of 2024 amounted to ¥17.33 billion, reflecting a 4.66% increase from ¥16.56 billion at the end of 2023[21]. - The company reported a basic earnings per share of ¥0.0135 for 2024, compared to a loss of ¥0.3267 per share in 2023, marking a 104.13% improvement[21]. - The net profit after deducting non-recurring gains and losses for 2024 was a loss of ¥76.64 million, an improvement of 88.26% from a loss of ¥652.82 million in 2023[21]. - The company reported a weighted average return on equity of 0.24% for 2024, recovering from -5.34% in 2023[21]. - The total operating revenue for 2024 was approximately ¥20.05 billion, a decrease of 1.60% compared to ¥20.38 billion in 2023[48]. - Revenue from agricultural product processing and sales accounted for 98.62% of total revenue, amounting to approximately ¥19.78 billion, down 1.44% from ¥20.06 billion in 2023[48]. - The fuel ethanol and its by-products generated revenue of approximately ¥9.83 billion, representing 49.00% of total revenue, with a year-on-year increase of 1.26%[48]. - The starch and its by-products saw revenue of approximately ¥3.48 billion, which is 17.36% of total revenue, reflecting a growth of 6.22% compared to the previous year[48]. - The company's total operating costs decreased by 3.97% year-over-year, with the main business cost accounting for 99.13% of total operating costs[51]. - The company reported a significant decrease in net cash flow from operating activities, dropping by 92.04% to ¥155,812,469.74 compared to the previous year[58]. - The total cash inflow from financing activities was 6,876,677,833.76, a decrease of 10.14% compared to the previous year, while cash outflow from financing activities decreased by 25.40% to 6,365,231,504.81[59]. - The net increase in cash and cash equivalents was 318,137,277.44, reflecting a 38.35% decrease year-on-year[59]. - The company reported a total of 50,000 shares repurchased by Chen Shaohui, with 25,000 shares remaining after the buyback[97]. - The company reported a total revenue of 231.55 million for the period, with a year-on-year increase of 50%[134]. - The total revenue for the company reached CNY 16,149.28 million, with a net profit of CNY 1,043.89 million, reflecting a significant performance in the reporting period[176]. Market Position and Strategy - The company plans to continue its market expansion and product development strategies without committing to specific future financial outcomes[4]. - The company aims to enhance its market presence in the eastern and northwestern regions of China for starch sugar products[42]. - The company plans to expand its starch syrup project in Chengdu, with a capacity of 150,000 tons, expected to be operational by 2025, enhancing supply capabilities in the Southwest region[37]. - The company is actively exploring cutting-edge technologies in biodegradable materials, optimizing key processes for lactate extraction and purification[39]. - The company aims to maintain its leading position in the bioenergy sector while expanding into high-end alcohol and biodegradable materials, focusing on a "cost leadership + technological innovation" strategy[82]. - The company plans to enhance its product structure by extending the starch industry chain, with a focus on starch sugar, functional sugars, modified starch, and fermentation products[82]. - The company is actively adjusting its industrial structure to expand the market for high-value-added and small-packaged alcohol products, as well as developing CO2 and feed products[82]. - The company is exploring potential mergers and acquisitions to strengthen its market position[149]. - The company plans to implement a new marketing strategy that focuses on digital channels, aiming for a 30% increase in online sales[163]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[167]. Research and Development - The company has a total of 638 authorized patents and has participated in the formulation of over 100 industry standards as of the end of 2024[43]. - Research and development expenses decreased by 22.05% to ¥128,828,371.66, while the number of R&D personnel fell by 30.09% to 295[56][57]. - The company has invested 200 million RMB in R&D for new technologies aimed at improving production efficiency by 30%[162]. - The company has invested 500 million RMB in R&D for new technologies aimed at improving production efficiency by 25%[167]. - The company is actively developing new technologies for waste treatment, enhancing operational efficiency[158]. Environmental Compliance and Sustainability - The company is committed to complying with various environmental protection laws and regulations, including the Environmental Protection Law and the Air Pollution Prevention Law[142]. - The company has established a carbon management system and has certified 16 domestic enterprises, enhancing compliance and performance in carbon management[177]. - The company has implemented a dedicated annual budget for environmental protection, ensuring that funds are used exclusively for maintaining and improving environmental performance[173]. - The company has established emergency response plans for environmental incidents, with annual training and drills conducted for relevant personnel, improving emergency response capabilities[169]. - The company has reported a total of 6.36 million RMB in environmental detection costs, including online monitoring expenses, reflecting its commitment to environmental oversight[174]. - The company has achieved compliance with emission standards across various facilities, demonstrating commitment to environmental responsibility[158]. - The company has established a comprehensive monitoring plan for pollutants, including pH, COD, and nitrogen levels, to ensure environmental safety[159]. - The company is focused on enhancing its wastewater treatment capabilities to further reduce pollutant discharge[153]. - The company has implemented advanced wastewater treatment processes, including pre-treatment, high-efficiency anaerobic treatment, and chemical phosphorus removal, achieving stable discharge standards[154]. - The company has established robust storage facilities that meet environmental protection requirements, preventing leakage and ensuring safe disposal practices[154]. - The company has reported a significant reduction in pollutant discharge levels, contributing to overall environmental protection efforts[154]. - The company is actively pursuing a net-zero emissions pathway, engaging professional consultants to optimize its carbon reduction goals and strategies[179]. Corporate Governance and Management - The company’s governance structure includes a board of directors and supervisory board ensuring the accuracy and completeness of financial reports[4]. - The company held six temporary shareholder meetings in 2024, with investor participation rates ranging from 55.52% to 56.80%[94]. - The company has seen a significant turnover in its board of directors, with multiple resignations and appointments occurring in 2024[98]. - The total annual remuneration for directors, supervisors, and senior management in 2024 is 7.3503 million yuan (pre-tax), including basic salary, bonuses, allowances, and various insurance fees[107]. - The board held a total of 14 meetings during the reporting period, with an average attendance rate of 71%[111]. - The company actively engaged in discussions and provided valuable suggestions to enhance decision-making processes[113]. - The company has implemented a comprehensive performance and compensation management system for senior management, linking performance bonuses to company effectiveness and work performance[134]. - The company has reported zero significant defects in both financial and non-financial internal controls during the evaluation period[139]. Employee Engagement and Training - The total number of employees at the end of the reporting period was 5,261, with 451 in the parent company and 4,810 in major subsidiaries[118]. - The company trained 53,133 employees with a total training investment of CNY 472,000 and 4,985 training hours in 2024[121]. - The professional composition of employees includes 4,120 production personnel, 300 sales personnel, 501 technical personnel, 190 financial personnel, and 150 administrative personnel[118]. - The educational background of employees shows 115 with master's degrees or higher, 1,048 with bachelor's degrees, 1,146 with associate degrees, and 2,952 with vocational or lower education[119]. - The company emphasizes a performance-oriented salary management approach, linking income levels to performance results to stimulate employee potential[120]. Shareholder Relations - The company reported a positive profit available for distribution to shareholders but did not propose a cash dividend distribution for the 2024 fiscal year[123]. - The company has not implemented any cash dividend distribution, stock issuance, or capital reserve conversion to increase share capital for the fiscal year[124]. - The company completed the liquidation of Huanglong Food Industry Co., Ltd. in June 2024, indicating a change in the consolidation scope[53]. - The company has maintained a good integrity status, with no significant debts or court judgments unmet[198]. - The total amount of related party transactions during the reporting period was 220.23 million yuan, which did not exceed the approved limit[199]. Risk Management - The company effectively controlled price and exchange rate fluctuation risks through derivative investments, reporting a derivative profit of 36,562,000.00 for the period[72]. - The company is aligning its operational strategies to mitigate risks associated with competition and asset management[91]. - The company has established a monitoring system for pollutants, with third-party verification to ensure compliance with environmental standards[173].

Financial Performance - The company's operating revenue for Q1 2025 was ¥4,385,440,510.90, a decrease of 7.31% compared to ¥4,731,528,010.13 in the same period last year[5] - Net profit attributable to shareholders was ¥40,531,495.76, representing a significant increase of 63.17% from ¥24,840,311.23 year-on-year[5] - Net profit for the current period is CNY 41,783,602.69, an increase of 69.59% compared to CNY 24,640,657.00 in the previous period[17] - The company reported a total profit of CNY 58,260,380.33, up 14.44% from CNY 50,993,167.99 in the previous period[17] - Basic and diluted earnings per share increased to CNY 0.0218 from CNY 0.0134 in the previous period[17] Cash Flow - The net cash flow from operating activities improved to -¥256,367,445.32, an 81.88% increase compared to -¥1,414,584,529.72 in the previous year[5] - Cash inflow from operating activities totaled CNY 5,182,926,501.75, down from CNY 5,929,009,821.95 in the previous period[19] - Net cash flow from financing activities was 608,948,544.87, a decrease from 1,504,712,206.77 in the previous period[21] - Total cash and cash equivalents at the end of the period amounted to 1,676,139,351.71, down from 1,797,191,625.92 at the beginning of the period[21] - The net increase in cash and cash equivalents was -121,052,274.21, indicating a decline compared to -214,772,391.25 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥17,822,695,480.37, reflecting a 2.85% increase from the previous year[5] - Current assets amounted to CNY 7,333,681,599.88, up from CNY 6,810,032,146.29 at the start of the period[13] - Total liabilities increased to CNY 6,848,983,135.52 from CNY 6,412,706,650.24[14] - The company's total equity stood at CNY 10,973,712,344.85, reflecting a slight increase from the previous period[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 116,526[10] - The largest shareholder, COFCO Bio, holds 47.58% of the shares, totaling 883,233,262 shares[10] - The total equity attributable to shareholders increased slightly by 0.53% to ¥10,573,866,268.36[5] Research and Development - Research and development expenses rose by 76.09% to ¥53,907,076.70, indicating increased investment in innovation[8] - Research and development expenses increased to CNY 53,907,076.70, up 76.00% from CNY 30,614,055.85 in the previous period[16] Investment Income - The company reported a significant increase in investment income, which reached ¥32,100,905.52, a 470.52% rise compared to -¥8,663,739.90 in the previous year[8]

证券代码：000930 证券简称：中粮科技 公告编号：2025-020 中粮生物科技股份有限公司关于召开2024年度业绩说明会 的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 重要内容提示： ●会议时间：2025年4月27日 10:00-11:00 ●会议地点："路演中"网络直播参会 一、业绩说明会相关安排 ●会议方式：网络远程直播 ●会议内容：中粮生物科技股份有限公司（以下简称公司）将于2025年4月26日 披露《中粮生物科技股份有限公司2024年度报告》及其摘要，详情请参阅巨潮资讯网 （www.cninfo.com.cn）、《中国证券报》《证券时报》《证券日报》《上海证券报》。 为便于广大投资者更全面深入地了解公司2024年度经营业绩等情况，公司决定通过 "路演中"举行"2024年度业绩说明会"。 1.召开时间：2025年4月27日（星期日）10:00-11:00。 网络远程直播会议链接：https://www.roadshowchina.cn/w/meet/rwJbkp 会议二维码： （2）投资者可在2025年4月27日10:00-11:00通过拨打 ...